Investment, collaborations and bold strategy can make UK a pharma leader as Brexit looms, says report

17 January 2017

Collaborations with other companies, academia and catapults are increasingly central to the discovery and development of new medicines, says a new report on UK pharma.

The move away from the older model of closed corporate research and development labs and towards collaborative working and open innovation is highlighted as in the R&D sourcebook from the Association of the British Pharmaceutical Industry (ABPI), a trade group representing UK pharma companies.

"We are in a period of great change, not least with the UK embarking on a journey outside of the EU, but also as an industry"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK